Beta - Amyloid (1 - 15)

Description:

The Aβ1-14, Aβ1-15, and Aβ1-16 are elevated in cell media and in CSF in response to γ-secretase inhibitor treatment. The fragments can serve as biomarkers in clinical studies of the effect of such inhibitors. There is evidence that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged.

Sequence:

DAEFRHDSGYEVHHQ

General

References

Comments (0)

Name	Beta - Amyloid (1 - 15)
Category	Beta-Amyloidand Related Peptides
One Letter Code	DAEFRHDSGYEVHHQ
Three Letter Code	{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}{Val}{His}{His}{Gln}
Molecular Weight	1826.900
Application	Alzheimer's Disease

Portelius, Erik, et al. "Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patient." Neurodegenerative Diseases 10.1-4 (2012): 138-140.

Portelius, Erik, et al. "Novel AβIsoforms in Alzheimer's Disease-Their Role in Diagnosis and Treatment." Current pharmaceutical design 17.25 (2011): 2594-2602.

Portelius, Erik, et al. "A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease." Alzheimer's research & therapy 2.2 (2010): 7.

Gevorkian, Goar, et al. "Mimotopes of conformational epitopes in fibrillar β-amyloid." Journal of neuroimmunology 156.1-2 (2004): 10-20.